Skip Navigation Linksdefault

slide1.jpg 

Uniquely placed to optimise the properties of Microbial Natural Products

 

Isomerase Therapeutics is a drug discovery and development company based in Cambridge, UK, with particular expertise in the discovery and development of optimised microbial natural products. We offer a proven route to develop these hits into drugs via our unique biosynthetic medicinal chemistry services.

We offer this bespoke biosynthetic engineering/semi-synthetic chemistry platform and drug discovery and development expertise on a FTE basis to partners looking for more than just a CRO. Isomerase Therapeutics can help you take your chosen natural product from an interesting hit to a high value candidate drug.

 

​Collaborations

​Technology

​Internal Programs

​The team at Isomerase are uniquely placed to assist partners with their microbial natural product-based drug discovery programs, by applying a combination of biosynthetic engineering (bioengineering) and semi-synthetic chemistry.

  

We offer these biosynthetic medicinal chemistry services supported by a portfolio of technology IP and the combined experience of a core scientific team from over a decade of successful drug discovery and development collaborations with Pharma and Biotech companies. 

​Isomerase is committed to continuing development of its proprietary bioengineering technologies and bringing in cutting-edge synthetic biology platforms.

 

We are at the forefront of microbial natural product bioengineering and are actively exploring new methods for increasing chemical diversity, efficiency and yield of polyketides, non-ribosomal peptides and other microbial natural products.

​Isomerase is developing a defined portfolio of its own internal programmes in the infectious disease area which target Peptidyl-Prolyl Isomerases, in particular FKBPs.

 

We believe the stage is set for an increase in therapeutic agents that target isomerases due to significant recent strides in understanding the basis of their biology. We are applying our next-generation biosynthetic engineering to natural products that target isomerases to generate candidate drugs in areas of high unmet need.